medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2011, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2011; 9 (4)


Talidomida: de sus oscuros antecedentes, a las promesas futuras

Mancheno VA, Rosas MA, Sánchez AK, Ochoa SP, Zepeda LP, Arrazola GJ, Hajar ST, Isunza RA, Rodríguez CAA, Arenas R

Idioma: Español
Referencias bibliográficas: 104
Paginas: 298-305
Archivo PDF: 217.30 Kb.


RESUMEN

Después de la tragedia causada por los efectos teratogénicos de la talidomida, a finales de la década de 1950 e inicios de 1960, este medicamento ha resurgido de manera relevante para el tratamiento de múltiples enfermedades. A pesar de que hoy solo está aprobado por la FDA para eritema nudoso leproso y mieloma múltiple, se usa extensamente en otras patologías.
Gracias a sus mecanismos de acción y a sus efectos antiinflamatorios, inmunomoduladores, y anti angiogénicos, se propone como un fármaco de gran utilidad en el campo de la dermatología. Los efectos terapéuticos, hasta el momento, son promisorios en la mayoría de los casos. Los mejores resultados se han descrito en el prúrigo actínico, el eritema nudoso leproso, la estomatitis aftosa, la enfermedad de Behçet, el lupus eritematoso, y el prúrigo nodular. No obstante, su seguridad sigue generando controversia en la literatura actual.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. George J, McBride Elias S. “Thalidomide and the Titanic: Reconstructing the technology tragedies of the Twentieth Century”. Am J Public Health 1999; 89(1): 98-101.

  2. Chávez Viamontes JA, Quiñones Hernández J, Fernández Hernández O. “Talidomida, contextos históricos y éticos”. Rev Hum Méd 2009; 9(3). Disponible en http: //scielo.sld.cu/scielo.php.

  3. Radomsky CL, Levine N. “Thalidomide”. Dermatol Clinics 2001; 19(1): 87-103.

  4. Vega ME, Hojyo MT, Domínguez L. “Tratamiento del prúrigo actínico con talidomida. Estudio en 30 pacientes”. Rev Mex Dermatol 1993; 37(Suppl 1): 342-343.

  5. Chen M, Doherty S, Hsu S. “Innovative Uses of Thalidomide”. Dermatol Clin 2010; (28): 577-586.

  6. Pintado Vázquez S. “La catástrofe de la talidomida en el cincuentenario de su comercialización”. JANO 2009: 1: 726.

  7. Moghe V, Ujjwala P. “Thalidomide”. Bombay Hospital Journal 2008; 50(3): 446.

  8. Botting J. “The History of Thalidomide”. Drug News Perspect 2002; 15(9): 604-611.

  9. Diggle G. “Thalidomide: 40 years on”. Int J Clin Pract 2001; 55(9): 627- 631.

  10. McBride WG. “Thalidomide and congenital abnormalities”. Lancet 1962; 1: 45.

  11. Lenz W. “Thalidomide and congenital abnormalities”. Lancet 1961; 4: 1358.

  12. International Clearinghouse for Birth Defects Surveillance and Research. [En línea]. URL disponible en: http: //www.icbd.org Consultado: Abril 12, 2009.

  13. Sigala C, Nelle H, Halabe J. “El resurgimiento de la talidomida”. Rev Fac Med UNAM 2001; (44): 5.

  14. Kelsey FO. “Thalidomide update: regulatory aspects”. Teratology 1988; 38: 221-226.

  15. Barnhill R, McDougall C. “Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions”. J Am Acad Dermatol 1982; 7: 317-323.

  16. Sheskin J. “Thalidomide in the treatment of lepra reactions”. Clin Pharmacol Ther 1965; 6: 303-306.

  17. Londoño F. “Thalidomide in the treatment of actinic prúrigo”. Int. J. Dermatol 1973; 12: 326-328.

  18. Calnan CD, Meara RH. “Actinic prúrigo (Hutchinson’s summer prúrigo)”. Clin Exp Dermatol 1977; 32: 365-372.

  19. Flores O. “Prúrigo solar de altiplanicie. Resultados preliminares de tratamiento con talidomida en 25 casos”. Rev Mex Dermatol 1975; 19: 26-39.

  20. Barba-Rubio J, Franco-González F. “Lupus eritematoso discoide y talidomida”. Dermatología Rev Mex 1975; 19: 131.

  21. Fernández Camacho Y, León Dorantes G. “Talidomida: una nueva oportunidad”. Rev Med Hosp Gen Mex 2000; 63 (3): 185-191.

  22. Melchert M, List A. “The thalidomide saga”. Int J Biochem Cell Biol 2007; 39(7-8): 1489-1499.

  23. Tseng S, Pak G, Washenik K, et al. “Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses”. J Am Acad Dermatol 1996; 35(6): 969-979.

  24. Stirling DI. “Thalidomide and its impact in dermatology”. Semin in Cutan Med Surg 1988; 17(4): 231-242.

  25. Grosshans E, Illy G. “Thalidomide therapy for inflammatory dermatoses”. Int J Dermatol 1984; 23(9): 598-602.

  26. Mellin GW, Katzenstein M. “The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities”. N Engl J Med 1962; 23: 1184-1190.

  27. Sharma N, Sharma V, Mahajan V, Shanker V, Ranjan N, Gupta M. “Thalidomide: An experience in therapeutic outcome and adverse reactions”. J Dermatol Treat 2007; 18: 335-340

  28. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. “Identification of a primary target of thalidomide teratogenicity”. Science 2010; (327): 1345-1350.

  29. Chen TL, Vogelsang GB, Petty BG. “Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers”. Drug Metab Dispos 1989; 17: 402-405.

  30. Schumacher H, Smith RL, Williams RT. “The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species”. Br J Pharmacol 1965; 25: 338-351.

  31. Braun AG, Harding FA, Weinreb SL. “Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450”. Toxicol Appl Pharmacol 1986; 82: 175-179.

  32. Nasca MR, O’Toole EA, Palicharla P, et al. “Thalidomide increases human keratinocyte migration and proliferation”. J Invest Dermatol 1999; 113(5): 720-724.

  33. Warren NJ. “ThalomidTM package insert“. Celgene Corporation 1997.

  34. Calabrese L, Fleischer AB. “Thalidomide: current and potential clinical applications“. Am J Med 2000; 108(6): 487-495.

  35. Moreira AL, Sampaio EP, Zmuidzinas A, et al. “Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation“. J Exp Med 1993; 177: 1675-1680.

  36. McHugh SM, Rifkin IR, Deighton J, et al. “The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures“. Clin Exp Immunol 1995; 99: 160-167.

  37. Stephens TD. “Proposed mechanisms of action in thalidomide embryopathy”. Teratology 1988; 38: 229-239.

  38. Sheskin J. “The treatment of lepra reaction in lepromatous leprosy: fifteen years experience with thalidomide“. Int J Dermatol 1980; 19: 318-322.

  39. Lewis WR. “Treatment of leprosy in the United States”. Bull NY Acad Med 1984; 60: 696-711.

  40. Jew LJ. “Thalidomide in erythema nodosum leprosum”. Ann Pharmacoter 1990; 24: 482-483.

  41. Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P. “Neurological toxicity of long-term (41 year) thalidomide therapy in patients with multiple myeloma”. Eur J Haematol 2005; 74: 212-216.

  42. Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, Olivieri A, et al. “Common and rare side-effects of low dose thalidomide in multiple myeloma: focus on the dose minimizing peripheral neuropathy”. Eur J Haematol 2004; 72: 403-409.

  43. Bruno B, et al. “New drugs for treatment of multiple myeloma”. Lancet Oncol 2004; 5: 430-442.

  44. Saylan T, Saltik I. “Thalidomide in the treatment of Behcet’s syndrome”. Arch Dermatol 1982; 118: 536.

  45. Munro CS, Cox NH. “Pyoderma gangrenosum associated with Behcet’s syndrome — response to thalidomide”. Clin Exp Dermatol 1988; 13(6): 408-410.

  46. Heney D, Bailey CC, Lewis IL. “Thalidomide for chronic graft versus host disease”. Lancet 1990; 44: 199-204.

  47. Heney D, Norfolk DR, Wheeldon J. “Thalidomide treatment for chronic graft versus host disease”. Br J Haematol 1991; 78: 23-27.

  48. McCarthy DM, Kanfer EJ, Barret AJ. “Thalidomide for the therapy of graft versus host disease following allogenic bone marrow transplantation”. Biomed Pharmacoter 1989; 43: 693-697.

  49. Grunfeld C, Feingold K. “Metabolic disturbances and wasting in the acquired immunodeficiency syndrome”. N Eng J Med 1992; 327(5): 329-335.

  50. Sharpstone D, Rowbottom A, Nelson M, Lepper M, Gazzard B. “Faecal tumour necrosis factors-alpha in individuals with HIV-related diarrhea”. AIDS 1996; 10: 989-994.

  51. Barba Rubio J, Franco González F. “Lupus eritematoso discoide. Informe preliminar”. Rev Mex Dermatol 1972; 21: 131-139.

  52. Naafs B, Bakkers EJM, Flinterman J, et al. “Thalidomide treatment of subacute cutaneous lupus erythematosus”. Br J Dermatol 1982; 107: 83-86.

  53. Sosa V, et al. “Tratamiento comparativo entre talidomida y factor de transferencia en dermatitis atópica severa”. Alergia Méx 2001; 48(2): 56-63.

  54. Arenas R; Dermatología. Atlas, diagnóstico y tratamiento. 4ta ed. México Mc. Graw Hill, 2009: 411-426.

  55. Lovell CR, Hawk JL, Calnan CD, Magnus IA. “Thalidomide in actinic prúrigo”. Br J Dermatol 1983; 108: 467-471.

  56. Johnke H, Zachariae H. “Thalidomide treatment of prúrigo nodularis”. Ugeskr Laeger 1993; 155: 3028-3030.

  57. Moulin G, Bonnet F, Barrut D, Franc MP. “Treatment of Jessner-Kanof disease with thalidomide”. Ann Dermatol Venereol 1983; 110: 611-614.

  58. Guillaume JC, Moulin G, Dieng MT et al. “Crossover study of thalidomide vs placebo in Jessner’s lymphocytic infiltration of the skin”. Arch Dermatol 1995; 131: 1032-1035.

  59. Silva SR, Viana PC, Lugon NV, et al. “Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial”. Nephron 1994; 67: 270-273.

  60. George SJ, Hsu S. “Lichen planopilaris treated with thalidomide”. J Am Acad Dermatol 2001; 45: 965-966.

  61. Camisa C, Popovsky JL. “Effective treatment of oral erosive lichen planus with thalidomide”. Arch Dermatol 2000; 136: 1442-1443.

  62. Cherouati K, Claudy A, Souteyrand P, et al. “Treatment by thalidomide of chronic multiform erythema: its recurrent and continuous variants. A retrospective study of 26 patients”. Ann Dermatol Venereol 1996; 123: 375-377.

  63. Barriere H. “Sarcoides cutanées. Traité par la thalidomide”. Presse Med 1983; 12: 963.

  64. Doherty CB, Rosen T. “Evidence-based therapy for cutaneous sarcoidosis”. Drugs 2008; 68(10): 1361-1383.

  65. Lee JB, Koblenzer PS. “Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report”. J Am Acad Dermatol 1998; 39: 835-838.

  66. Estines O, Revuz J, Wolkenstein P, et al. “Sarcoidosis: thalidomide treatment in ten patients”. Ann Dermatol Venereol 2001; 128(5): 611- 613.

  67. Baughman RP, Judson MA, Teirstein AS, et al. “Thalidomide for chronic sarcoidosis”. Chest 2002; 122(1): 227-232.

  68. Federman GL, Federman DG. “Recalcitrant pyoderma gangrenosum treated with thalidomide”. Mayo Clin Proc 2000; 75(8): 842-844.

  69. Venencie PY, Saurat JH. “Pyoderma gangrenosum in a child: treatment with thalidomide”. Ann Pediatr 1982; 29: 67-69.

  70. Hecker MS, Lebwohl MG. “Recalcitrant pyoderma gangrenosum: treatment with thalidomide”. J Am Acad Dermatol 1998; 38: 490-501.

  71. Farrell AM, Black MM, Bracka A, et al. “Pyoderma gangrenosum of the penis”. Br J Dermatol 1998; 138(2): 337-340

  72. Peter LM, Ammoury A, Chiavassa-Gandois H, et al. “Scleromyxedema with associated peripheral neuropathy: successful treatment with thalidomide”. Clin Exp Dermatol 2008; 33(5): 606-610.

  73. Amini-Adle M, Thieulent N, Dalle S, et al. “Scleromyxedema: successful treatment with thalidomide in two patients”. Dermatology 2007; 214(1): 58-60.

  74. Wu MY, Hong JB, Yang CC, et al. “Scleromyxedema with myopathy was successfully treated by thalidomide”. J Eur Acad Dermatol Venereol 2009; 23(2): 189-190.

  75. Sansbury JC, Cocuroccia B, Jorizzo JL, et al. “Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients”. J Am Acad Dermatol 2004; 51(1): 126-131.

  76. Kukreja T, Petersen J. “Thalidomide for the treatment of refractory necrobiosis lipoidica”. Arch Dermatol 2006; 142(1): 20-22.

  77. Padula A, Medeiros LJ, Silva EG, et al. “Isolated vulvar Langerhans cell histiocytosis: report of two cases”. Int J Gynecol Pathol 2004; 23(3): 278- 283.

  78. Broekaert SM, Metzler G, Burgdorf W, et al. “Multisystem Langerhanscell histiocytosis: successful treatment with thalidomide”. Am J Clin Dermatol 2007; 8(5): 311-314.

  79. McClain KL, Kozinetz CA. “A phase II trial using thalidomide for Langerhans cell histiocytosis”. Pediatr Blood Cancer 2007; 48(1): 44-49.

  80. Mimura MA, Hirota SK, Sugaya NN, et al. “Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial”. Clinics (Sao Paulo) 2009; 64(3): 193-198.

  81. Bowers PW, Powell RJ. “Effect of thalidomide on orogenital ulceration”. Br Med J (Clin Res Ed) 1983; 287(6395): 799-800.

  82. De Wazieres B, Gil H, Magy N, et al. “Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients”. Rev Med Interne 1999; 20(7): 567-570.

  83. Wu JJ, Huang DB, Pang KR, et al. “Thalidomide: dermatological indications, mechanisms of action and side-effects”. Br J Dermatol 2005; 153(2): 254-273.

  84. Drake LA, Dinehart SM, Farmer ER, et al. “Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology”. J Am Acad Dermatol 1996; 34(5 Pt 1): 830-836.

  85. Maurer T, Poncelet A, Berger T. “Thalidomide treatment for prúrigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy”. Arch Dermatol 2004; 140: 845-849.

  86. Koch HP. “Thalidomide and congeners as anti-inflammatory agents”. Prog Med Chem 1985; 22: 165-242.

  87. Passeron T, Lacour JP, Murr D, Ortonne JP. “Thalidomide-induced amenorrhoea: two cases”. Br J Dermatol 2001; 144: 1292-1293.

  88. Pouaha J, Martin S, Reichert-Penetrat S et al. “Thalidomide and sexual dysfunction in men”. Br J Dermatol 2002; 146: 1112-1113.

  89. Bielsa I, Teixido J, Ribera M, Ferrandiz C. “Erythroderma due to thalidomide: report of two cases”. Dermatology 1994; 189: 179-181.

  90. Rajkumar SV, Gertz MA, Witzig TE. “Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma”. N Engl J Med 2000; 343: 972-973.

  91. Dobson CM, Parslew RA. “Exacerbation of psoriasis by thalidomide in Behcet’s syndrome”. Br J Dermatol 2003; 149: 432-433.

  92. McBride WG. “Thalidomide embryopathy”. Teratology 1977; 16: 79-

  93. Ochonisky S, Verroust J, Bastuji-Garin S, Gheradi R, Revuz J. “Thalidomide neuropathy incidence and clinic electro physiologic findings in 42 patients”. Arch Dermatol 1994; 130: 66-69.

  94. Bastuji-Garin S, Ochonisky S, Bouche P et al. “Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients”. J Invest Dermatol 2002; 119: 1020-1026.

  95. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. “Development of neuropathy in patients with myeloma treated with thalidomide – patterns of occurrence and the role of electrophysiologic monitoring”. J Clin Oncol 2006; 24: 4507-4514.

  96. De Longh RU. “A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus”. J Neuropathol Exp Neurol 1990; 49: 564-581.

  97. Cundari S, Cavaletti G. “Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives”. Mini Reviews in Medicinal Chemistry 2009; 9: 760-768.

  98. Isoardo G, et al. “Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features”. Acta Neurol. Scand 2004; 109: 188-193.

  99. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. “Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro”. J Neuro Oncology 1999; 43: 109-114.

  100. Sharma NL, Sharma V, Shanker V, Mahajan VK, Sarin S. “Deep vein thrombosis: A rare complication of thalidomide therapy in recurrent erythema nodosum leprosum”. Int J Lepr Other Mycobact Dis 2004; 72: 483-485.

  101. Williams I, Weller IV, Malni A, et al. “Thalidomide hypersensitivity in AIDS”. Lancet 1991; 337: 436-437.

  102. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. “S.T.E.P.S: a comprehensive program for controlling and monitoring access to thalidomide”. Clin Ther 1999; 21: 319-330.

  103. Hess CW, Hunziker T, Kupfer A, et al. “Thalidomide-induced peripheral neuropathy. A perspective clinical, neurophysiological and pharmacogenetic evaluation”. J Neurol 1986; 233(2): 83-89.

  104. Powell RJ, Gardner-Medwin JMM. “Guideline for the clinical use and dispensing of thalidomide”. Postgrad Med J 1994; 70: 901-904.




2020     |     www.medigraphic.com